Immutep Limited (IMMP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Immutep Limited (IMMP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.93

0.00 (0.00%)

At close: Jan 15, 2025, 1:44 PM

undefined% (undefined)

Bid	1.93
Market Cap	281.02M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.23
PE Ratio (ttm)	-8.39
Forward PE	n/a
Analyst	Buy

Ask	1.94
Volume	58,143
Avg. Volume (20D)	119,509
Open	1.95
Previous Close	1.93
Day's Range	1.91 - 1.95
52-Week Range	1.66 - 3.34
Beta	undefined

About IMMP

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, wh...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 19, 2012

Employees 41

Stock Exchange NASDAQ

Ticker Symbol IMMP

Website https://www.immutep.com

Analyst Forecast

According to 2 analyst ratings, the average rating for IMMP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 340.28% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+11.76%

Immutep shares are trading higher after the compan... Unlock content with Pro Subscription

4 months ago · Source

-12.5%

Immutep shares are trading lower. The company announced efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha in combination with MSD's anti-PD-1 therapy KEYTRUDA as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients.

News

2 months ago · seekingalpha.com

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data fr...

2 months ago · benzinga.com

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy for fi...